-
Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
Cell death and differentiation 20161201
-
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function.
Oncotarget 20160920
-
Role of the protein kinase BRAF in the pathogenesis of endometriosis.
Expert opinion on therapeutic targets 20160801
-
BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
Cancer medicine 20160601
-
HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.
Cancer research 20160501
-
Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
British journal of cancer 20160315
-
Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
The EMBO journal 20160301
-
Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
The Journal of clinical endocrinology and metabolism 20160301
-
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
European journal of cancer (Oxford, England : 1990) 20160301
-
MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
Endocrine-related cancer 20160301
-
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Oncotarget 20160126
-
Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity.
PloS one 20160101
-
Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma.
PloS one 20160101
-
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
Scientific reports 20160101
-
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Cancer chemotherapy and pharmacology 20151101
-
RAF inhibitors that evade paradoxical MAPK pathway activation.
Nature 20151022
-
Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib.
ACS chemical biology 20150918
-
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Cancer cell 20150914
-
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
Chemical research in toxicology 20150518
-
The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells.
The Journal of biological chemistry 20150116
-
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.
eLife 20150101
-
PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells.
Journal of Cancer 20150101
-
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Journal of medicinal chemistry 20141009
-
Identification of recurrent SMO and BRAF mutations in ameloblastomas.
Nature genetics 20140701
-
Copper is required for oncogenic BRAF signalling and tumorigenesis.
Nature 20140522
-
Characterization of vemurafenib phototoxicity in a mouse model.
Toxicological sciences : an official journal of the Society of Toxicology 20140101
-
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters 20130801
-
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
Expert opinion on drug metabolism & toxicology 20130701
-
BRAF inhibitor activity in V600R metastatic melanoma.
European journal of cancer (Oxford, England : 1990) 20130301
-
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma.
Scientific reports 20130101
-
Vemurafenib for the treatment of melanoma.
Expert opinion on pharmacotherapy 20121201
-
Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Molecular pharmaceutics 20121105
-
Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
International journal of cancer 20121101
-
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.
The British journal of dermatology 20121101
-
Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.
Melanoma research 20121001
-
Vemurafenib: in unresectable or metastatic melanoma.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20121001
-
Conformation-specific effects of Raf kinase inhibitors.
Journal of medicinal chemistry 20120913
-
Combining pharmacophore, docking and substructure search approaches to identify and optimize novel B-RafV600E inhibitors.
Bioorganic & medicinal chemistry letters 20120901
-
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology 20120901
-
From chemotherapy to targeted treatment.
Annals of oncology : official journal of the European Society for Medical Oncology 20120901
-
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Nature 20120726
-
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
The Journal of pharmacology and experimental therapeutics 20120701
-
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Part 2.
Bioorganic & medicinal chemistry letters 20120701
-
Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Clinical therapeutics 20120701
-
Receptor tyrosine kinases in cancer escape from BRAF inhibitors.
Cell research 20120601
-
Early [18F]fluorodeoxyglucose-positron emission tomography responses in metastatic melanoma: what do they mean?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120510
-
Narrowing the knowledge gaps for melanoma.
Upsala journal of medical sciences 20120501
-
New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: design, synthesis, and antiproliferative activity against melanoma cell line.
Bioorganic & medicinal chemistry letters 20120501
-
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
Future oncology (London, England) 20120501
-
Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Future oncology (London, England) 20120501
-
A case of vemurafenib-induced keratosis pilaris-like eruption.
Dermatology online journal 20120415
-
Upcoming strategies for the treatment of metastatic melanoma.
Archives of dermatological research 20120401
-
Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120315
-
Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Archives of dermatology 20120301
-
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.
Current opinion in oncology 20120301
-
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Archives of dermatology 20120301
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
The New England journal of medicine 20120223
-
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Cancer research 20120215
-
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
The Journal of clinical endocrinology and metabolism 20120201
-
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Cancer research 20120201
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Nature 20120126
-
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120120
-
Drug approvals 2011: focus on companion diagnostics.
Journal of the National Cancer Institute 20120118
-
Small molecule inhibitors of BRAF in clinical trials.
Bioorganic & medicinal chemistry letters 20120115
-
Challenges ahead for companion diagnostics.
Journal of the National Cancer Institute 20120104
-
Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120101
-
Specifically targeting ERK1 or ERK2 kills melanoma cells.
Journal of translational medicine 20120101
-
Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis.
Internal medicine (Tokyo, Japan) 20120101
-
[BRAF mutation: a novel approach in targeted melanoma therapy].
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20120101
-
Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.
PloS one 20120101
-
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Nature 20111215
-
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
The Journal of clinical investigation 20111201
-
Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
Neoplasia (New York, N.Y.) 20111201
-
[Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Postepy higieny i medycyny doswiadczalnej (Online) 20111123
-
Larger companies dominate cancer companion diagnostic approvals.
Nature biotechnology 20111108
-
Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
The Annals of pharmacotherapy 20111101
-
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
The Journal of investigative dermatology 20111001
-
New drugs in melanoma: it's a whole new world.
European journal of cancer (Oxford, England : 1990) 20110901
-
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Cancer research 20110801
-
Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.
Drugs 20110709
-
Strides in melanoma announced: maximizing value comes next.
Journal of the National Cancer Institute 20110706
-
From genome to drugs: where do we stand?
Journal of the National Cancer Institute 20110706
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
The New England journal of medicine 20110630
-
BRAF targeted therapy changes the treatment paradigm in melanoma.
Nature reviews. Clinical oncology 20110524
-
A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110501
-
Overcoming metastatic melanoma with BRAF inhibitors.
Archives of pharmacal research 20110501
-
Early accelerated approval for highly targeted cancer drugs.
The New England journal of medicine 20110324
-
BRAF as a target for cancer therapy.
Anti-cancer agents in medicinal chemistry 20110301
-
Equipoise and the dilemma of randomized clinical trials.
The New England journal of medicine 20110203
-
The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).
Biochemical and biophysical research communications 20110128
-
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
Journal of translational medicine 20110101
-
[Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition].
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20110101
-
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
PloS one 20110101
-
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Nature 20101216
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nature 20101216
-
Inhibition of mutated BRAF in melanoma.
The New England journal of medicine 20101202
-
Oncogenic RAF: a brief history of time.
Pigment cell & melanoma research 20101201
-
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
Pigment cell & melanoma research 20101201
-
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Nature 20100930
-
Inhibition of mutated, activated BRAF in metastatic melanoma.
The New England journal of medicine 20100826
-
PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
Current opinion in investigational drugs (London, England : 2000) 20100601
-
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Pigment cell & melanoma research 20100401
-
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
Journal of translational medicine 20100101
-
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
Journal of translational medicine 20100101